These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420 [TBL] [Abstract][Full Text] [Related]
3. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Kugler KC; Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 1999 May; 34(1):73-6. PubMed ID: 10342111 [TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057 [TBL] [Abstract][Full Text] [Related]
5. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Defife R; Scheetz MH; Feinglass JM; Postelnick MJ; Scarsi KK Antimicrob Agents Chemother; 2009 Mar; 53(3):1074-9. PubMed ID: 19075047 [TBL] [Abstract][Full Text] [Related]
6. Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains. Credito K; Lin G; Koeth L; Sturgess MA; Appelbaum PC Antimicrob Agents Chemother; 2009 Feb; 53(2):814-7. PubMed ID: 19015359 [TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Wenzel RP; Sahm DF; Thornsberry C; Draghi DC; Jones ME; Karlowsky JA Antimicrob Agents Chemother; 2003 Oct; 47(10):3089-98. PubMed ID: 14506014 [TBL] [Abstract][Full Text] [Related]
8. [In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002]. Yamaguchi K; Ohno A; Kashitani F; Iwata M; Kanda M; Tsujio Y; Shimoyama N; Okujima H; Ito M; Kawaguchi H; Chiba H; Akizawa K; Katayama Y; Sugimoto K; Tashiro H; Kaimori M; Suwabe A; Obata R; Sugiyama T; Toyoshima S; Kato J; Kaku M; Kanemitsu K; Kunishima H; Okada J; Tazawa Y; Igari J; Oguri T; Watanabe K; Kobayashi Y; Uchida H; Totsuka K; Kon S; Nakamura K; Matsuda K; Hayashi I; Shiotani J; Shiotani J; Kanno H; Itoh A; Sumitomo M; Uchida T; Kawabata A; Oiwa C; Iwata M; Horii T; Ishigo S; Yoshimura T; Ichiyama S; Wada Y; Kimura S; Maesaki S; Itoh K; Noda Y; Yamashita T; Yamaguchi I; Kageyama F; Shaku E; Baba H; Inuzuka K; Okabe H; Tatewaki K; Moro K; Aihara M; Matsushima T; Niki Y; Kuw Abara M; Ikawa S; Tanaka M; Hinoda Y; Sugiura T; Kamioka M; Ono J; Takata T; Makino H; Murase M; Miyamoto H; Aizawa H; Honda J; Takii M; Nagasawa Z; Aoki Y; Hamazaki N; Tsutsui T; Nakagawa K; Iwata M; Hiramatsu K; Saikawa T; Yamane N; Kimoto H; Kotani T; Kageoka T; Hongo T; Masuda J; Miyanohara H; Tsujimura M; Yasujima M; Hayashi I Jpn J Antibiot; 2005 Feb; 58(1):17-44. PubMed ID: 15849869 [TBL] [Abstract][Full Text] [Related]
9. HACEK endocarditis: a review. Sharara SL; Tayyar R; Kanafani ZA; Kanj SS Expert Rev Anti Infect Ther; 2016 Jun; 14(6):539-45. PubMed ID: 27124204 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Frei CR; Burgess DS Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390 [TBL] [Abstract][Full Text] [Related]
12. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone]. Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547 [TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of various antibiotic agents against gram-negative nosocomial bacteremia pathogens]. Gür D; Kocagöz T; Akalin HE Mikrobiyol Bul; 1992 Jul; 26(3):233-41. PubMed ID: 1528143 [TBL] [Abstract][Full Text] [Related]
14. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
15. Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. Pfaller MA; Barry AL; Fuchs PC J Clin Microbiol; 1993 Jul; 31(7):1924-6. PubMed ID: 8349777 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of viridans group streptococci. Tuohy M; Washington JA Diagn Microbiol Infect Dis; 1997 Dec; 29(4):277-80. PubMed ID: 9458986 [TBL] [Abstract][Full Text] [Related]
17. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Hsueh PR; Chen WH; Luh KT Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243 [TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens]. Noviello S; Ianniello F; Leone S; Esposito S Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239 [TBL] [Abstract][Full Text] [Related]